Provided by Tiger Trade Technology Pte. Ltd.

BOAN BIOTECH

2.890
-0.060-2.03%
Volume:876.20K
Turnover:2.53M
Market Cap:1.77B
PE:199.26
High:2.990
Open:2.990
Low:2.815
Close:2.950
52wk High:13.050
52wk Low:2.400
Shares:614.00M
HK Float Shares:614.00M
Volume Ratio:0.53
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.015
ROE:-4.11%
ROA:-1.28%
PB:0.57
PE(LYR):199.26
PS:2.43

Loading ...

Shandong Boan Biotechnology Expects Net Loss Attributable of RMB79 Million-RMB89 Million

Reuters
·
Aug 14

Shandong Boan Biotech Completes China Phase Ia Trial of Ba1302 CD228-Targeted ADC

Reuters
·
Aug 14

Shandong Boan Biotechnology Co - Expected Turnaround to Loss Mainly Due to Increased R&D Expenditure in Hy

THOMSON REUTERS
·
Aug 14

Shandong Boan Biotech Schedules Board Meeting on Interim Results, Dividend Review

Reuters
·
Aug 14

Hong Kong Stock Movers: BOAN BIOTECH Surges Over 3% Before Noon as Aflibercept Injection Seeks Brazilian Approval

Stock News
·
Aug 11

BOAN BIOTECH Affirms Stable 622.33 Million Share Base and Meets Public-Float Waiver in July 2026 Return

Bulletin Express
·
Aug 06

Shandong Boan Biotechnology Submits BLA for Ba9101 to Anvisa in Brazil

Reuters
·
Aug 05

Shandong Boan Files Brazil Marketing Application for Ba9101 Aflibercept Biosimilar with Anvisa

Reuters
·
Aug 05

Shandong Boan Biotechnology Co - Submits Bla for Ba9101 to Anvisa in Brazil

THOMSON REUTERS
·
Aug 05

Shandong Boan Biotechnology's Cancer Drug Candidate Gets IND Acceptance; Shares Down 5%

MT Newswires Live
·
Jul 08

BOAN BIOTECH’s BA1203 IND Accepted by CDE, Marking China’s First Masked PD-1/IL-2 Fusion Protein to Enter Clinical Trials

Bulletin Express
·
Jul 08

Shandong Boan Says China CDE Accepts IND Filing for Ba1203 Masked Anti-pd-1/il-2 Fusion Protein

Reuters
·
Jul 08

Shandong Boan Biotechnology Co - Cde Accepts Ind Application for Ba1203 Targeting Pd-1 and Il-2

THOMSON REUTERS
·
Jul 08

Shandong Boan Biotechnology - Acceptance from China's Cde of Nmpa

THOMSON REUTERS
·
Jul 08

Shandong Boan Biotechnology Gets Trial Nod for Lung Cancer Drug in China

MT Newswires Live
·
Jul 02

Boan Biotech Secures CDE Approval to Advance BA1106 + BA1104 Combo into Phase II Trial for Driver-Gene-Negative NSCLC

Bulletin Express
·
Jul 02

Shandong Boan Biotechnology Co - Cde Approves Phase Ii Trial of Anti-cd25 Antibody with Pd-1 Inhibitor for Nsclc

THOMSON REUTERS
·
Jul 02

Shandong Boan Biotech shareholders adopt restricted share unit incentive scheme at AGM

Reuters
·
Jun 22

Boan Biotechnology Licenses Diabetes Drug Biosimilar in US

MT Newswires Live
·
Jun 12

BOAN BIOTECH Grants U.S. Rights for BA5101, the First Trulicity® Biosimilar, in Licensing Agreement

Bulletin Express
·
Jun 11